Fulcrum Therapeutics Acquires Global Rights to Losmapimod, a Potential Disease-Modifying Therapy for Facioscapulohumeral Muscular Dystrophy

CAMBRIDGE, Mass., April 23, 2019 – Fulcrum Therapeutics, a biotechnology company focused on discovering and developing therapies to rebalance gene expression, today announced an exclusive worldwide license agreement with GlaxoSmithKline (GSK) for development and commercialization of the investigational drug losmapimod. Fulcrum intends to advance losmapimod into a Phase 2b trial in the rare and devastating genetic disease facioscapulohumeral muscular dystrophy (FSHD), for which there are currently no approved treatments.

Read more

Fulcrum Therapeutics Appoints Christopher Moxham, Ph.D. as SVP, Discovery

Cambridge, Mass. –February 20, 2019 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced further growth of their leadership team with the appointment of Christopher Moxham, Ph.D. as senior vice president of discovery.

Read more

Fulcrum Therapeutics to Present at Biotech Showcase 2019

Cambridge, Mass. – January 4, 2019 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, will present at next week’s Biotech Showcase in San Francisco.

Read more

Fulcrum Therapeutics Appoints Biotech Executive Bryan Stuart as Chief Operating Officer

Cambridge, Mass. – January 3, 2019 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced the appointment of Bryan E. Stuart as chief operating officer.

Read more

Fulcrum Therapeutics Announces $80 Million Series B Financing

Cambridge, Mass., September 5, 2018 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced the closing of an $80 million Series B financing. Proceeds from the financing will be used to advance Fulcrum’s lead program in facioscapulohumeral muscular dystrophy (FSHD) into clinical testing, and to progress its pipeline of therapeutics for rare, genetically-based neuromuscular, central nervous system and hematologic disorders.

Read More

Fulcrum Therapeutics Promotes Diego Cadavid, M.D., to Senior Vice President, Clinical Development

Cambridge, Mass., August 14, 2018 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies that unlock gene regulation to treat serious genetic diseases, today announced the promotion of Diego Cadavid, M.D., formerly Vice President, Clinical Development, to Senior Vice President, Clinical Development.

Read More

Fulcrum Therapeutics Strengthens Board of Directors with Appointment of Kate Haviland

Cambridge, Mass., June 27, 2018 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced the appointment of Kate Haviland, Chief Business Officer of Blueprint Medicines, to its Board of Directors. 

Read More

Fulcrum Therapeutics and the FSHD Clinical Trial Research Network Announce Clinical Trial Readiness Study

Cambridge, Mass., May 21, 2018 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, and the FSHD Clinical Trial Research Network (CTRN) today announced the initiation of a clinical trial readiness study.

Read More